SciTechDaily
Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first cell-based treatment for the neurodegenerative retinal disease known as MacTel. For individuals with macular telangiectasia type 2 (MacTel), a rare retinal disease that steadily erodes central vision, no approved therapies had previously existed…
Read More
First-Ever Treatment for Rare Eye Disease Wins FDA Approval After Landmark Trials
Scripps Research Institute
22:27
Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first cell-based treatment for the neurodegenerative retinal disease known as MacTel. For individuals with macular telangiectasia type 2 (MacTel), a rare retinal disease that steadily erodes central vision, no approved therapies had previously existed…
